Canada Liver Disease Therapeutics Market Report 2022 to 2030

Canada Liver Diseases Therapeutics Market Analysis

$ 3999

Canada's liver disease therapeutics market is likely to grow at a CAGR of 5.7% from a market size of $1.84 Bn in 2022 to $2.87 Bn in 2030. The increase in alcohol consumption along with the change in lifestyle and increasing geriatric population acts as a market growth driver. This report is segmented by treatment type, disease type, and by distribution channel. Some key players in this market include AbbVie, Novartis, Bristol-Myers & Squibb, Merck, Roche, Eli Lilly, and others.

ID: IN10CAPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Dhruv Joshi

Buy Now

Canada Liver Disease Therapeutics Market executive summary

Canada's liver disease therapeutics market size is at around $1.84 Bn in 2022 and is projected to reach $2.87 Bn in 2030, exhibiting a CAGR of 5.7% during the forecast period 2022-2030. Canada is one of the biggest nations in the world and the biggest in the western hemisphere. It boasts a thriving free-market economy with companies ranging from tiny owner-managed businesses to global corporations. Canada's economy has historically been based on the export of agricultural commodities, especially grain, as well as the production and sale of natural resource exports including minerals, oil and gas, and forest products.

canada liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

Alcohol consumption and an unhealthy lifestyle are the main causes of the rising prevalence of liver disorders such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, and liver cancer worldwide. Moreover, an increase in the elderly population around the world contributes to disease dysfunction. As a result, there has been an increase in hospital admissions for both hereditary genetic illnesses and the different liver diseases indicated above. One of the main causes of liver problems is a significant increase in alcohol use since it causes certain liver cells to die during the alcohol-filtering process, which results in the accumulation of scar tissue in the liver. Although the liver may grow new cells, excessive drinking can hinder this process and increase the risk of irreversible damage. Although the liver may grow new cells, excessive drinking can hinder this process and increase the risk of irreversible damage. Alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis are the three liver conditions associated with heavy drinking and are together referred to as alcohol-related liver disease or alcoholic liver disease.

Poor eating habits and an unhealthy lifestyle also contribute to weight increase, which furthers the development of obesity. The two main factors contributing to fatty liver disease in adulthood are obesity and alcoholism. As a result of being overweight or obese, fat builds up in the liver. This results in persistent inflammation and liver scarring (also known as cirrhosis). Obesity and non-alcoholic fatty liver disease are closely related. Excess fat leads to insulin resistance and inflammatory signals.

Market Restraints

The Canadian market for liver disease is constrained by a number of factors. The following are some of the major elements influencing this market's expansion: Inadequate knowledge: There is a dearth of knowledge regarding liver illnesses, their symptoms, and the available therapies among the general public. This makes it challenging for pharmaceutical companies to advertise their goods and connect with potential customers. The high treatment costs also hamper the market growth. Treating liver illnesses can be expensive, especially when they are in advanced stages. For patients who might not be able to pay for the treatments, this can be a significant obstacle.

Competitive Landscape

Key Players

AbbVie
Bristol-Myers & Squibb Company
Novartis
Merck
Roche
Eli Lilly
Gilead
Sanofi

Healthcare Policies and Regulatory Landscape

Health Canada, which is in charge of regulating and approving medications and medical equipment, is in charge of Canada's healthcare regulations for liver illnesses. Prior to being certified for use in Canada, Health Canada verifies that all medications and medical devices are secure, efficient, and of the highest caliber. Another agency that is vital to Canada's regulation of healthcare is the Canadian Agency for Drugs and Technologies in Health (CADTH). To evaluate the effectiveness of new pharmaceuticals and medical equipment from a clinical and financial standpoint, CADTH performs health technology assessments. These evaluations aid in decision-making regarding the treatments that will be covered by government and private insurance programs. In addition, the Canadian Liver Foundation (CLF) is a nonprofit group that supports and educates patients with liver illnesses as well as promotes liver health. Research into the causes and cures for liver illnesses is also supported by the CLF. In general, the regulatory policy in Canada for liver illnesses aims to guarantee that patients have access to safe and efficient therapies and that the healthcare system is capable of providing these treatments in a way that is both efficient and affordable.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Canada Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.